FRAZER, Pa., April 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq:
CEPH) announced today that Jerry Pappert has been appointed Executive Vice
President and General Counsel. In this position, Mr. Pappert will manage
all legal affairs for the company, including those relating to commercial
and financial transactions, litigation, intellectual property and corporate
and securities matters. Reporting directly to Chairman and CEO, Frank
Baldino Jr., Ph.D., he will serve on the company's Executive Committee. Mr.
Pappert will join the company on May 12.
"We are fortunate to have an attorney of Jerry's caliber join our
leadership team," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "Jerry
exemplifies the professional leadership qualities we value and his
strategic advice and counsel will help us navigate the increasingly
intersecting environment of legal and business issues."
Mr. Pappert brings 20 years of legal experience, which includes eight
years with the Commonwealth of Pennsylvania, as Attorney General from 2003
to 2005 and First Deputy Attorney General from 1997 to 2003. Since leaving
the Attorney General's office, Pappert has been a partner with Ballard
Spahr Andrews & Ingersoll LLP in Philadelphia where he has been a member of
the Litigation Department. Prior to his tenure in Harrisburg, he conducted
a commercial litigation practice within a large Philadelphia law firm.
A graduate of Villanova University, Mr. Pappert earned his Juris
Doctorate from the University of Notre Dame Law School in South Bend,
Indiana.
Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical
company dedicated to the discovery, development and commercialization of
innovative products in four core therapeutic areas: central nervous system,
pain, oncology and addiction. A member of the Fortune 1000, Cephalon
currently employs approximately 3,000 people in the United States and
Europe. U.S. sites include the company's headquarters in Frazer,
Pennsylvania, and offices, laboratories or manufacturing facilities in West
Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis,
Minnesota. The company's European headquarters are located in
Maisons-Alfort, France.
The company's proprietary products in the United States include:
AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules),
TREANDA(R) (bendamustine hydrochloride) for Injection, FENTORA(R) (fentanyl
buccal tablet) [C-II], PROVIGIL(R) (modafinil) Tablets [C-IV], TRISENOX(R)
(arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release
injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM)
(armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl
citrate) [C-II]. The company also markets numerous products
internationally. Full prescribing information on its U.S. products is
available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition,
this press release may contain forward-looking statements. Forward-looking
statements provide Cephalon's current expectations or forecasts of future
events. These may include statements regarding anticipated scientific
progress on its research programs, development of potential pharmaceutical
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects for
its products, sales and earnings guidance, and other statements regarding
matters that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements such as
"anticipate," "estimate," "expect," "project," "intend," "plan," "believe"
or other words and terms of similar meaning. Cephalon's performance and
financial results could differ materially from those reflected in these
forward-looking statements due to general financial, economic, regulatory
and political conditions affecting the biotechnology and pharmaceutical
industries as well as more specific risks and uncertainties facing Cephalon
such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed
with the U.S. Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may prove to
be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Cephalon does not intend to update
publicly any forward-looking statement, except as required by law. The
Private Securities Litigation Reform Act of 1995 permits this discussion.
SOURCE Cephalon, Inc.
 back to top
Related links:
http://www.cephalon.com
http://www.prnewswire.com/comp/134563.html /
CONTACT:
Media: Sheryl Williams, +1-610-738-6493,
swilliam@cephalon.com, or Investors: Robert (Chip) Merritt,
+1-610-738-6376, cmerritt@cephalon.com
|
